Clinical prediction of Parkinson's disease: planning for the age of neuroprotection

R B Postuma
September 2010
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010, Vol. 81 Issue 9, p1008
Academic Journal
As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.


Related Articles

  • NEWSBRIEFS.  // Mind, Mood & Memory;Feb2013, Vol. 9 Issue 2, p2 

    The article presents news briefs on the findings of several studies on adult brain health. Speed-learning a foreign language can reportedly stimulate the brain's growth. Another study investigated how depression affects the health of people with Parkinson's disease. One study examined how...

  • Beyond tremor and rigidity: non-motor features of Parkinson’s disease. Löhle, Matthias; Storch, Alexander; Reichmann, Heinz // Journal of Neural Transmission;Nov2009, Vol. 116 Issue 11, p1483 

    Parkinson’s disease (PD) is the second most common neurodegenerative disease and primarily considered as a movement disorder defined by the presence of motor symptoms, such as bradykinesia, tremor and rigidity. However, it is nowadays widely accepted that PD is associated with a wide...

  • Country cardiograms case 27: Answer. Helm, Charles // Canadian Journal of Rural Medicine;Summer2005, Vol. 10 Issue 3, p191 

    Discusses the use of tricyclics as first-line treatment for depression, chronic pain syndromes and fibromyalgia. Risk of overdose from tricyclics; Estimate of the dosage based on patient weight; Monitor of seizure management, fluid balance, electrolyte balance, and alkalinization of serum pH.

  • Parkinson Disease Guidelines Aid Diagnosis, Management. Voelker, Rebecca // JAMA: Journal of the American Medical Association;5/10/2006, Vol. 295 Issue 18, p2126 

    This article discusses the development of guidelines aimed at improving Parkinson disease diagnosis and management. The American Academy of Neurology has released guidelines that address Parkinson disease comprehensively. These guidelines describe how physicians can recognize Parkinson disease...

  • Depression in Parkinson's disease. Schwarz, J.; Odin, P.; Buhmann, C.; Csoti, I.; Jost, W.; Wüllner, U.; Storch, A. // Journal of Neurology;May2011, Vol. 258 Issue 2, p336 

    mong the recently well appreciated non-motor symptoms in Parkinson's disease (PD), depression plays a prominent role due to its frequency and impact on quality of life. However, depression may be confounded by motor symptoms, especially akinesia and other non-motor symptoms such as apathy,...

  • Cognitive and Affective Impairment in Parkinson Disease - A B.I.N. Experience. Ghosh, T.; Das, S. K.; Basu, J.; Mishra, A. // Annals of Indian Academy of Neurology;2007 Supplement 2, Vol. 10, p43 

    Background: The presence of cognitive and affective impairments in Parkinson's disease is well-documented around the world. There is paucity of work on this subject in Indian medical literature. Objective: To determine the cognitive and affective impairments in patients with Idiopathic...

  • Psychiatric aspects of Parkinson's disease. Baldwin, R.C.; Byrne, E.J. // BMJ: British Medical Journal (International Edition);7/1/89, Vol. 298 Issue 6690, p3 

    Examines the psychiatric aspect of Parkinson's disease (PD). Development of dementia in PD patients; Increase susceptibility to severe depression; Occurrence of psychotic disturbance caused by antiparkinsonian drugs.

  • Parkinson Hastalığı Sırasında Ortaya Çıkan Psikotik Özellikli Manik Atak: Olgu Sunumu. Karakuş, Gonca; Özpoyraz, Nurgül; Zengin, Meliha; Tamam, Lut; Vura, Ayşe; Koç, Filiz // Klinik Psikiyatri Dergisi;2012, Vol. 15 Issue 4, p248 

    Parkinson's disease is a chronic and progressive neurode-generative disease. Psychiatric symptoms and disorders are a common cooccurrence in people with Parkinson's disease. Psychiatric symptoms and disorders may be direct result of Parkinson's disease, its comorbid patholo-gies, or occur as a...

  • The Impact of Clinical and Cognitive Variables on Social Functioning in Parkinson's Disease: Patient versus Examiner Estimates. McNamara, Patrick; Stavitsky, Karina; Durso, Raymon; Harris, Erica // Parkinson's Disease (20420080);2010, p1 

    Purpose. To assess the impact of clinical variables on social skills and behaviors in Parkinson's disease (PD) patients and patient versus examiner estimates of social functioning. Methods. Twenty-eight patients with PD and 32 controls with chronic disease were assessed with a battery of...


Read the Article


Sign out of this library

Other Topics